

Global Spinal Muscular Atrophy (SMA) Therapeutic Market Insight and Forecast to 2026

<https://marketpublishers.com/r/G6ED948D7A44EN.html>

Date: August 2020

Pages: 174

Price: US\$ 2,350.00 (Single User License)

ID: G6ED948D7A44EN

Abstracts

The research team projects that the Spinal Muscular Atrophy (SMA) Therapeutic market size will grow from XXX in 2019 to XXX by 2026, at an estimated CAGR of XX. The base year considered for the study is 2019, and the market size is projected from 2020 to 2026.

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing with 10 major regions and 30 major countries. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

By Market Players:

Biogen

Astellas Pharma

Novartis

Roche

Genzyme Corporation

By Type

Nusinersen

Onasemnogen Apeparvovec

By Application

Nusinersen SMA

Onasemnogen Abeparvovec SMA

Other

By Regions/Countries:

North America

United States

Canada

Mexico

East Asia

China

Japan

South Korea

Europe

Germany

United Kingdom

France

Italy

South Asia

India

Southeast Asia

Indonesia

Thailand

Singapore

Middle East

Turkey

Saudi Arabia

Iran

Africa

Nigeria

South Africa

Oceania
Australia

South America

Points Covered in The Report

The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.

The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analyzed 12 years data history and forecast.

The growth factors of the market is discussed in detail wherein the different end users of the market are explained in detail.

Data and information by market player, by region, by type, by application and etc, and custom research can be added according to specific requirements.

The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Reasons to Purchase

To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.

Assess the production processes, major issues, and solutions to mitigate the development risk.

To understand the most affecting driving and restraining forces in the market and its impact in the global market.

Learn about the market strategies that are being adopted by leading respective organizations.

To understand the future outlook and prospects for the market.

Besides the standard structure reports, we also provide custom research according to specific requirements.

The report focuses on Global, Top 10 Regions and Top 50 Countries Market Size of Spinal Muscular Atrophy (SMA) Therapeutic 2015-2020, and development forecast 2021-2026 including industries, major players/suppliers worldwide and market share by

regions, with company and product introduction, position in the market including their market status and development trend by types and applications which will provide its price and profit status, and marketing status & market growth drivers and challenges, with base year as 2019.

Key Indicators Analysed

Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2015-2020 & Sales by Product Types.

Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2021-2026. Further the report provides break down details about each region & countries covered in the report. Identifying its production, consumption, import & export, sales volume & revenue forecast.

Market Analysis by Product Type: The report covers majority Product Types in the Spinal Muscular Atrophy (SMA) Therapeutic Industry, including its product specifications by each key player, volume, sales by Volume and Value (M USD).

Market Analysis by Application Type: Based on the Spinal Muscular Atrophy (SMA) Therapeutic Industry and its applications, the market is further sub-segmented into several major Application of its industry. It provides you with the market size, CAGR & forecast by each industry applications.

Market Trends: Market key trends which include Increased Competition and Continuous Innovations.

Opportunities and Drivers: Identifying the Growing Demands and New Technology

Porters Five Force Analysis: The report will provide with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

COVID-19 Impact

Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Spinal Muscular Atrophy (SMA) Therapeutic market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

Contents

1 REPORT OVERVIEW

- 1.1 Study Scope
- 1.2 Key Market Segments
- 1.3 Players Covered: Ranking by Spinal Muscular Atrophy (SMA) Therapeutic Revenue
- 1.4 Market Analysis by Type
 - 1.4.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size Growth Rate by Type: 2020 VS 2026
 - 1.4.2 Nusinersen
 - 1.4.3 Onasemnogen Abeparvovec
- 1.5 Market by Application
 - 1.5.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Application: 2021-2026
 - 1.5.2 Nusinersen SMA
 - 1.5.3 Onasemnogen Abeparvovec SMA
 - 1.5.4 Other
- 1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
 - 1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
 - 1.6.2 Covid-19 Impact: Commodity Prices Indices
 - 1.6.3 Covid-19 Impact: Global Major Government Policy
- 1.7 Study Objectives
- 1.8 Years Considered

2 GLOBAL GROWTH TRENDS

- 2.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Market Perspective (2021-2026)
- 2.2 Spinal Muscular Atrophy (SMA) Therapeutic Growth Trends by Regions
 - 2.2.1 Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Regions: 2015 VS 2021 VS 2026
 - 2.2.2 Spinal Muscular Atrophy (SMA) Therapeutic Historic Market Size by Regions (2015-2020)
 - 2.2.3 Spinal Muscular Atrophy (SMA) Therapeutic Forecasted Market Size by Regions (2021-2026)

3 MARKET COMPETITION BY MANUFACTURERS

3.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Production Capacity Market Share by Manufacturers (2015-2020)

3.2 Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share by Manufacturers (2015-2020)

3.3 Global Spinal Muscular Atrophy (SMA) Therapeutic Average Price by Manufacturers (2015-2020)

4 SPINAL MUSCULAR ATROPHY (SMA) THERAPEUTIC PRODUCTION BY REGIONS

4.1 North America

4.1.1 North America Spinal Muscular Atrophy (SMA) Therapeutic Market Size (2015-2026)

4.1.2 Spinal Muscular Atrophy (SMA) Therapeutic Key Players in North America (2015-2020)

4.1.3 North America Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2015-2020)

4.1.4 North America Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2015-2020)

4.2 East Asia

4.2.1 East Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size (2015-2026)

4.2.2 Spinal Muscular Atrophy (SMA) Therapeutic Key Players in East Asia (2015-2020)

4.2.3 East Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2015-2020)

4.2.4 East Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2015-2020)

4.3 Europe

4.3.1 Europe Spinal Muscular Atrophy (SMA) Therapeutic Market Size (2015-2026)

4.3.2 Spinal Muscular Atrophy (SMA) Therapeutic Key Players in Europe (2015-2020)

4.3.3 Europe Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2015-2020)

4.3.4 Europe Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2015-2020)

4.4 South Asia

4.4.1 South Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size (2015-2026)

4.4.2 Spinal Muscular Atrophy (SMA) Therapeutic Key Players in South Asia (2015-2020)

4.4.3 South Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type

(2015-2020)

4.4.4 South Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2015-2020)

4.5 Southeast Asia

4.5.1 Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size (2015-2026)

4.5.2 Spinal Muscular Atrophy (SMA) Therapeutic Key Players in Southeast Asia (2015-2020)

4.5.3 Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2015-2020)

4.5.4 Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2015-2020)

4.6 Middle East

4.6.1 Middle East Spinal Muscular Atrophy (SMA) Therapeutic Market Size (2015-2026)

4.6.2 Spinal Muscular Atrophy (SMA) Therapeutic Key Players in Middle East (2015-2020)

4.6.3 Middle East Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2015-2020)

4.6.4 Middle East Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2015-2020)

4.7 Africa

4.7.1 Africa Spinal Muscular Atrophy (SMA) Therapeutic Market Size (2015-2026)

4.7.2 Spinal Muscular Atrophy (SMA) Therapeutic Key Players in Africa (2015-2020)

4.7.3 Africa Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2015-2020)

4.7.4 Africa Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2015-2020)

4.8 Oceania

4.8.1 Oceania Spinal Muscular Atrophy (SMA) Therapeutic Market Size (2015-2026)

4.8.2 Spinal Muscular Atrophy (SMA) Therapeutic Key Players in Oceania (2015-2020)

4.8.3 Oceania Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2015-2020)

4.8.4 Oceania Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2015-2020)

4.9 South America

4.9.1 South America Spinal Muscular Atrophy (SMA) Therapeutic Market Size (2015-2026)

4.9.2 Spinal Muscular Atrophy (SMA) Therapeutic Key Players in South America

(2015-2020)

4.9.3 South America Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2015-2020)

4.9.4 South America Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2015-2020)

4.10 Rest of the World

4.10.1 Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Market Size (2015-2026)

4.10.2 Spinal Muscular Atrophy (SMA) Therapeutic Key Players in Rest of the World (2015-2020)

4.10.3 Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Type (2015-2020)

4.10.4 Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Market Size by Application (2015-2020)

5 SPINAL MUSCULAR ATROPHY (SMA) THERAPEUTIC CONSUMPTION BY REGION

5.1 North America

5.1.1 North America Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries

5.1.2 United States

5.1.3 Canada

5.1.4 Mexico

5.2 East Asia

5.2.1 East Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries

5.2.2 China

5.2.3 Japan

5.2.4 South Korea

5.3 Europe

5.3.1 Europe Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries

5.3.2 Germany

5.3.3 United Kingdom

5.3.4 France

5.3.5 Italy

5.3.6 Russia

5.3.7 Spain

5.3.8 Netherlands

5.3.9 Switzerland

5.3.10 Poland

5.4 South Asia

5.4.1 South Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries

5.4.2 India

5.4.3 Pakistan

5.4.4 Bangladesh

5.5 Southeast Asia

5.5.1 Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries

5.5.2 Indonesia

5.5.3 Thailand

5.5.4 Singapore

5.5.5 Malaysia

5.5.6 Philippines

5.5.7 Vietnam

5.5.8 Myanmar

5.6 Middle East

5.6.1 Middle East Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries

5.6.2 Turkey

5.6.3 Saudi Arabia

5.6.4 Iran

5.6.5 United Arab Emirates

5.6.6 Israel

5.6.7 Iraq

5.6.8 Qatar

5.6.9 Kuwait

5.6.10 Oman

5.7 Africa

5.7.1 Africa Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries

5.7.2 Nigeria

5.7.3 South Africa

5.7.4 Egypt

5.7.5 Algeria

5.7.6 Morocco

5.8 Oceania

5.8.1 Oceania Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries

5.8.2 Australia

5.8.3 New Zealand

5.9 South America

5.9.1 South America Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries

5.9.2 Brazil

5.9.3 Argentina

5.9.4 Columbia

5.9.5 Chile

5.9.6 Venezuela

5.9.7 Peru

5.9.8 Puerto Rico

5.9.9 Ecuador

5.10 Rest of the World

5.10.1 Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries

5.10.2 Kazakhstan

6 SPINAL MUSCULAR ATROPHY (SMA) THERAPEUTIC SALES MARKET BY TYPE (2015-2026)

6.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Historic Market Size by Type (2015-2020)

6.2 Global Spinal Muscular Atrophy (SMA) Therapeutic Forecasted Market Size by Type (2021-2026)

7 SPINAL MUSCULAR ATROPHY (SMA) THERAPEUTIC CONSUMPTION MARKET BY APPLICATION(2015-2026)

7.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Historic Market Size by Application (2015-2020)

7.2 Global Spinal Muscular Atrophy (SMA) Therapeutic Forecasted Market Size by Application (2021-2026)

8 COMPANY PROFILES AND KEY FIGURES IN SPINAL MUSCULAR ATROPHY (SMA) THERAPEUTIC BUSINESS

8.1 Biogen

8.1.1 Biogen Company Profile

- 8.1.2 Biogen Spinal Muscular Atrophy (SMA) Therapeutic Product Specification
- 8.1.3 Biogen Spinal Muscular Atrophy (SMA) Therapeutic Production Capacity, Revenue, Price and Gross Margin (2015-2020)
- 8.2 Astellas Pharma
 - 8.2.1 Astellas Pharma Company Profile
 - 8.2.2 Astellas Pharma Spinal Muscular Atrophy (SMA) Therapeutic Product Specification
 - 8.2.3 Astellas Pharma Spinal Muscular Atrophy (SMA) Therapeutic Production Capacity, Revenue, Price and Gross Margin (2015-2020)
- 8.3 Novartis
 - 8.3.1 Novartis Company Profile
 - 8.3.2 Novartis Spinal Muscular Atrophy (SMA) Therapeutic Product Specification
 - 8.3.3 Novartis Spinal Muscular Atrophy (SMA) Therapeutic Production Capacity, Revenue, Price and Gross Margin (2015-2020)
- 8.4 Roche
 - 8.4.1 Roche Company Profile
 - 8.4.2 Roche Spinal Muscular Atrophy (SMA) Therapeutic Product Specification
 - 8.4.3 Roche Spinal Muscular Atrophy (SMA) Therapeutic Production Capacity, Revenue, Price and Gross Margin (2015-2020)
- 8.5 Genzyme Corporation
 - 8.5.1 Genzyme Corporation Company Profile
 - 8.5.2 Genzyme Corporation Spinal Muscular Atrophy (SMA) Therapeutic Product Specification
 - 8.5.3 Genzyme Corporation Spinal Muscular Atrophy (SMA) Therapeutic Production Capacity, Revenue, Price and Gross Margin (2015-2020)

9 PRODUCTION AND SUPPLY FORECAST

- 9.1 Global Forecasted Production of Spinal Muscular Atrophy (SMA) Therapeutic (2021-2026)
- 9.2 Global Forecasted Revenue of Spinal Muscular Atrophy (SMA) Therapeutic (2021-2026)
- 9.3 Global Forecasted Price of Spinal Muscular Atrophy (SMA) Therapeutic (2015-2026)
- 9.4 Global Forecasted Production of Spinal Muscular Atrophy (SMA) Therapeutic by Region (2021-2026)
 - 9.4.1 North America Spinal Muscular Atrophy (SMA) Therapeutic Production, Revenue Forecast (2021-2026)
 - 9.4.2 East Asia Spinal Muscular Atrophy (SMA) Therapeutic Production, Revenue

Forecast (2021-2026)

9.4.3 Europe Spinal Muscular Atrophy (SMA) Therapeutic Production, Revenue

Forecast (2021-2026)

9.4.4 South Asia Spinal Muscular Atrophy (SMA) Therapeutic Production, Revenue

Forecast (2021-2026)

9.4.5 Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Production,
Revenue Forecast (2021-2026)

9.4.6 Middle East Spinal Muscular Atrophy (SMA) Therapeutic Production, Revenue
Forecast (2021-2026)

9.4.7 Africa Spinal Muscular Atrophy (SMA) Therapeutic Production, Revenue
Forecast (2021-2026)

9.4.8 Oceania Spinal Muscular Atrophy (SMA) Therapeutic Production, Revenue
Forecast (2021-2026)

9.4.9 South America Spinal Muscular Atrophy (SMA) Therapeutic Production,
Revenue Forecast (2021-2026)

9.4.10 Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Production,
Revenue Forecast (2021-2026)

9.5 Forecast by Type and by Application (2021-2026)

9.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type
(2021-2026)

9.5.2 Global Forecasted Consumption of Spinal Muscular Atrophy (SMA) Therapeutic
by Application (2021-2026)

10 CONSUMPTION AND DEMAND FORECAST

10.1 North America Forecasted Consumption of Spinal Muscular Atrophy (SMA)
Therapeutic by Country

10.2 East Asia Market Forecasted Consumption of Spinal Muscular Atrophy (SMA)
Therapeutic by Country

10.3 Europe Market Forecasted Consumption of Spinal Muscular Atrophy (SMA)
Therapeutic by Country

10.4 South Asia Forecasted Consumption of Spinal Muscular Atrophy (SMA)
Therapeutic by Country

10.5 Southeast Asia Forecasted Consumption of Spinal Muscular Atrophy (SMA)
Therapeutic by Country

10.6 Middle East Forecasted Consumption of Spinal Muscular Atrophy (SMA)
Therapeutic by Country

10.7 Africa Forecasted Consumption of Spinal Muscular Atrophy (SMA) Therapeutic by
Country

10.8 Oceania Forecasted Consumption of Spinal Muscular Atrophy (SMA) Therapeutic by Country

10.9 South America Forecasted Consumption of Spinal Muscular Atrophy (SMA) Therapeutic by Country

10.10 Rest of the world Forecasted Consumption of Spinal Muscular Atrophy (SMA) Therapeutic by Country

11 MARKETING CHANNEL, DISTRIBUTORS AND CUSTOMERS

11.1 Marketing Channel

11.2 Spinal Muscular Atrophy (SMA) Therapeutic Distributors List

11.3 Spinal Muscular Atrophy (SMA) Therapeutic Customers

12 INDUSTRY TRENDS AND GROWTH STRATEGY

12.1 Market Top Trends

12.2 Market Drivers

12.3 Market Challenges

12.4 Porter's Five Forces Analysis

12.5 Spinal Muscular Atrophy (SMA) Therapeutic Market Growth Strategy

13 ANALYST'S VIEWPOINTS/CONCLUSIONS

14 APPENDIX

14.1 Research Methodology

14.1.1 Methodology/Research Approach

14.1.2 Data Source

14.2 Disclaimer

List Of Tables

LIST OF TABLES AND FIGURES

Table 1. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Type: 2020 VS 2026

Table 2. Nusinersen Features

Table 3. Onasemnogen Abeparvovec Features

Table 11. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Application: 2020 VS 2026

Table 12. Nusinersen SMA Case Studies

Table 13. Onasemnogen Abeparvovec SMA Case Studies

Table 14. Other Case Studies

Table 21. Commodity Prices-Metals Price Indices

Table 22. Commodity Prices- Precious Metal Price Indices

Table 23. Commodity Prices- Agricultural Raw Material Price Indices

Table 24. Commodity Prices- Food and Beverage Price Indices

Table 25. Commodity Prices- Fertilizer Price Indices

Table 26. Commodity Prices- Energy Price Indices

Table 27. G20+: Economic Policy Responses to COVID-19

Table 28. Spinal Muscular Atrophy (SMA) Therapeutic Report Years Considered

Table 29. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth 2021-2026 (US\$ Million)

Table 30. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Share by Regions: 2021 VS 2026

Table 31. North America Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2015-2026) (US\$ Million)

Table 32. East Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2015-2026) (US\$ Million)

Table 33. Europe Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2015-2026) (US\$ Million)

Table 34. South Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2015-2026) (US\$ Million)

Table 35. Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2015-2026) (US\$ Million)

Table 36. Middle East Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2015-2026) (US\$ Million)

Table 37. Africa Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2015-2026) (US\$ Million)

Table 38. Oceania Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY

Growth (2015-2026) (US\$ Million)

Table 39. South America Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2015-2026) (US\$ Million)

Table 40. Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Market Size YoY Growth (2015-2026) (US\$ Million)

Table 41. North America Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries (2015-2020)

Table 42. East Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries (2015-2020)

Table 43. Europe Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Region (2015-2020)

Table 44. South Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries (2015-2020)

Table 45. Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries (2015-2020)

Table 46. Middle East Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries (2015-2020)

Table 47. Africa Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries (2015-2020)

Table 48. Oceania Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries (2015-2020)

Table 49. South America Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries (2015-2020)

Table 50. Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Consumption by Countries (2015-2020)

Table 51. Biogen Spinal Muscular Atrophy (SMA) Therapeutic Product Specification

Table 52. Astellas Pharma Spinal Muscular Atrophy (SMA) Therapeutic Product Specification

Table 53. Novartis Spinal Muscular Atrophy (SMA) Therapeutic Product Specification

Table 54. Roche Spinal Muscular Atrophy (SMA) Therapeutic Product Specification

Table 55. Genzyme Corporation Spinal Muscular Atrophy (SMA) Therapeutic Product Specification

Table 101. Global Spinal Muscular Atrophy (SMA) Therapeutic Production Forecast by Region (2021-2026)

Table 102. Global Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume Forecast by Type (2021-2026)

Table 103. Global Spinal Muscular Atrophy (SMA) Therapeutic Sales Volume Market Share Forecast by Type (2021-2026)

Table 104. Global Spinal Muscular Atrophy (SMA) Therapeutic Sales Revenue Forecast

by Type (2021-2026)

Table 105. Global Spinal Muscular Atrophy (SMA) Therapeutic Sales Revenue Market Share Forecast by Type (2021-2026)

Table 106. Global Spinal Muscular Atrophy (SMA) Therapeutic Sales Price Forecast by Type (2021-2026)

Table 107. Global Spinal Muscular Atrophy (SMA) Therapeutic Consumption Volume Forecast by Application (2021-2026)

Table 108. Global Spinal Muscular Atrophy (SMA) Therapeutic Consumption Value Forecast by Application (2021-2026)

Table 109. North America Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2021-2026 by Country

Table 110. East Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2021-2026 by Country

Table 111. Europe Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2021-2026 by Country

Table 112. South Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2021-2026 by Country

Table 113. Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2021-2026 by Country

Table 114. Middle East Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2021-2026 by Country

Table 115. Africa Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2021-2026 by Country

Table 116. Oceania Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2021-2026 by Country

Table 117. South America Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2021-2026 by Country

Table 118. Rest of the world Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2021-2026 by Country

Table 119. Spinal Muscular Atrophy (SMA) Therapeutic Distributors List

Table 120. Spinal Muscular Atrophy (SMA) Therapeutic Customers List

Table 121. Porter's Five Forces Analysis

Table 122. Key Executives Interviewed

Figure 1. North America Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 2. North America Spinal Muscular Atrophy (SMA) Therapeutic Consumption Market Share by Countries in 2020

Figure 3. United States Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 4. Canada Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 5. Mexico Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 6. East Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 7. East Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption Market Share by Countries in 2020

Figure 8. China Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 9. Japan Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 10. South Korea Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 11. Europe Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate

Figure 12. Europe Spinal Muscular Atrophy (SMA) Therapeutic Consumption Market Share by Region in 2020

Figure 13. Germany Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 14. United Kingdom Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 15. France Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 16. Italy Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 17. Russia Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 18. Spain Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 19. Netherlands Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 20. Switzerland Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 21. Poland Spinal Muscular Atrophy (SMA) Therapeutic Consumption and

Growth Rate (2015-2020)

Figure 22. South Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate

Figure 23. South Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption Market Share by Countries in 2020

Figure 24. India Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 25. Pakistan Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 26. Bangladesh Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 27. Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate

Figure 28. Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption Market Share by Countries in 2020

Figure 29. Indonesia Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 30. Thailand Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 31. Singapore Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 32. Malaysia Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 33. Philippines Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 34. Vietnam Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 35. Myanmar Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 36. Middle East Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate

Figure 37. Middle East Spinal Muscular Atrophy (SMA) Therapeutic Consumption Market Share by Countries in 2020

Figure 38. Turkey Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 39. Saudi Arabia Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 40. Iran Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 41. United Arab Emirates Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 42. Israel Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 43. Iraq Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 44. Qatar Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 45. Kuwait Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 46. Oman Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 47. Africa Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate

Figure 48. Africa Spinal Muscular Atrophy (SMA) Therapeutic Consumption Market Share by Countries in 2020

Figure 49. Nigeria Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 50. South Africa Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 51. Egypt Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 52. Algeria Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 53. Morocco Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 54. Oceania Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate

Figure 55. Oceania Spinal Muscular Atrophy (SMA) Therapeutic Consumption Market Share by Countries in 2020

Figure 56. Australia Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 57. New Zealand Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 58. South America Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate

Figure 59. South America Spinal Muscular Atrophy (SMA) Therapeutic Consumption Market Share by Countries in 2020

Figure 60. Brazil Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth

Rate (2015-2020)

Figure 61. Argentina Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 62. Columbia Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 63. Chile Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 64. Venezuelal Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 65. Peru Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 66. Puerto Rico Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 67. Ecuador Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 68. Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate

Figure 69. Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Consumption Market Share by Countries in 2020

Figure 70. Kazakhstan Spinal Muscular Atrophy (SMA) Therapeutic Consumption and Growth Rate (2015-2020)

Figure 71. Global Spinal Muscular Atrophy (SMA) Therapeutic Production Capacity Growth Rate Forecast (2021-2026)

Figure 72. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Growth Rate Forecast (2021-2026)

Figure 73. Global Spinal Muscular Atrophy (SMA) Therapeutic Price and Trend Forecast (2015-2026)

Figure 74. North America Spinal Muscular Atrophy (SMA) Therapeutic Production Growth Rate Forecast (2021-2026)

Figure 75. North America Spinal Muscular Atrophy (SMA) Therapeutic Revenue Growth Rate Forecast (2021-2026)

Figure 76. East Asia Spinal Muscular Atrophy (SMA) Therapeutic Production Growth Rate Forecast (2021-2026)

Figure 77. East Asia Spinal Muscular Atrophy (SMA) Therapeutic Revenue Growth Rate Forecast (2021-2026)

Figure 78. Europe Spinal Muscular Atrophy (SMA) Therapeutic Production Growth Rate Forecast (2021-2026)

Figure 79. Europe Spinal Muscular Atrophy (SMA) Therapeutic Revenue Growth Rate Forecast (2021-2026)

Figure 80. South Asia Spinal Muscular Atrophy (SMA) Therapeutic Production Growth Rate Forecast (2021-2026)

Figure 81. South Asia Spinal Muscular Atrophy (SMA) Therapeutic Revenue Growth Rate Forecast (2021-2026)

Figure 82. Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Production Growth Rate Forecast (2021-2026)

Figure 83. Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Revenue Growth Rate Forecast (2021-2026)

Figure 84. Middle East Spinal Muscular Atrophy (SMA) Therapeutic Production Growth Rate Forecast (2021-2026)

Figure 85. Middle East Spinal Muscular Atrophy (SMA) Therapeutic Revenue Growth Rate Forecast (2021-2026)

Figure 86. Africa Spinal Muscular Atrophy (SMA) Therapeutic Production Growth Rate Forecast (2021-2026)

Figure 87. Africa Spinal Muscular Atrophy (SMA) Therapeutic Revenue Growth Rate Forecast (2021-2026)

Figure 88. Oceania Spinal Muscular Atrophy (SMA) Therapeutic Production Growth Rate Forecast (2021-2026)

Figure 89. Oceania Spinal Muscular Atrophy (SMA) Therapeutic Revenue Growth Rate Forecast (2021-2026)

Figure 90. South America Spinal Muscular Atrophy (SMA) Therapeutic Production Growth Rate Forecast (2021-2026)

Figure 91. South America Spinal Muscular Atrophy (SMA) Therapeutic Revenue Growth Rate Forecast (2021-2026)

Figure 92. Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Production Growth Rate Forecast (2021-2026)

Figure 93. Rest of the World Spinal Muscular Atrophy (SMA) Therapeutic Revenue Growth Rate Forecast (2021-2026)

Figure 94. North America Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2021-2026

Figure 95. East Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2021-2026

Figure 96. Europe Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2021-2026

Figure 97. South Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2021-2026

Figure 98. Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2021-2026

Figure 99. Middle East Spinal Muscular Atrophy (SMA) Therapeutic Consumption

Forecast 2021-2026

Figure 100. Africa Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2021-2026

Figure 101. Oceania Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2021-2026

Figure 102. South America Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2021-2026

Figure 103. Rest of the world Spinal Muscular Atrophy (SMA) Therapeutic Consumption Forecast 2021-2026

Figure 104. Channels of Distribution

Figure 105. Distributors Profiles

I would like to order

Product name: Global Spinal Muscular Atrophy (SMA) Therapeutic Market Insight and Forecast to 2026

Product link: <https://marketpublishers.com/r/G6ED948D7A44EN.html>

Price: US\$ 2,350.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G6ED948D7A44EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970